Healthcare
Longeveron® Appoints Marie Washburn as Chief Financial Officer
Marie Washburn Marie Washburn, Longeveron CFO Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results from the Phase 2b clinical trial evaluating its stem cell therapy in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 MIAMI, July 06, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-thr
About this update from Longeveron Inc.
Marie Washburn MIAMI, July 06, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Marie Washburn to the Company's executive leadership team in the role of Senior Vice President and Chief Financial Officer ("CFO"), principal financial officer and principal accounting officer, effective July 13, 2026. She succeeds Lisa Locklear who, as previously announced, is stepping down to pursue board opportunities and other professional and personal interests. "Marie has had a tremendously positive impact on the Company since joining last year and I am delighted to welcome her as CFO, particularly at this exciting time in Longeveron's history developing stem cell therapies for vulnerable populations," said Steven H. Willard, Chief Executive Officer of Longeveron. "With our Phase 2b clinical trial evaluating laromestrocel as a potential treatment for HLHS anticipated to produce top-line trial results in third quarter of this year, Longeveron is poised for a significant transformation of our business and development programs." Ms. Washburn commented, "This is an extraordinary time for Longeveron and our stem cell therapy laromestrocel. The Company is well positioned for continued success with a clear patient-focused approach, strong foundational science and impressive clinical data to date. I look forward to working with the Longeveron team to ensure the long-term success of laromestrocel while focusing on the Company's operational, financial and accounting functions." Ms. Washburn has served as the Company's Vice President and Corporate Controller since November 2025. Before joining the Company, Ms. Washburn spent over 20 years in the pharmaceutical and biotech sectors in leadership roles, most recently serving as the Vice President of Finance at Fore Biotherapeutics, Inc., a precision oncology company developing cancer therapies from January 2025 to June 2025; serving from December 2019 to June 2024 in multiple roles at Axcella Health, Inc., a clinical-stage biotechnology company targeting treatment of complex diseases using endogenous metabolic modulator (EMM) compositions, including as Executive Director, Accounting and Corporate Controller, Vice President of Finance, Acting ...